Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: Percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin

Annals of Oncology

Volumn 13, Issue 7, 2002, Pages 1151-1155

  Lee, K D ^a   Liu, T W ^a   Wu, C W ^b   Tiu, C M ^b   Liu, J M ^a   Chung, T R ^a   Chang, J Y ^a   Whang Peng, J ^a   Chen, L T ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Afferent lopp syndrome; High dose 5 fluorouracil leucovorin; Percutaneous transhepatic duodenal drainage

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; UFT; ANTINEOPLASTIC AGENT;

ADULT; AFFERENT LOOP SYNDROME; AGED; ARTICLE; CARCINOMATOUS PERITONITIS; CASE REPORT; CONSERVATIVE TREATMENT; DEVICE REMOVAL; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOXICITY; HUMAN; MALE; PERCUTANEOUS TRANSHEPATIC DRAINAGE; PRIORITY JOURNAL; RECURRENT CANCER; STOMACH CANCER; SYMPTOMATOLOGY; TUMOR REGRESSION; ADENOCARCINOMA; CARCINOMA; DOSE RESPONSE; FOLLOW UP; GASTRECTOMY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PERITONEAL DISEASE; PERITONEUM TUMOR; STOMACH TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE; WOUND DRAINAGE;

ADENOCARCINOMA; AFFERENT LOOP SYNDROME; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CASE REPORT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRAINAGE; FLUOROURACIL; FOLLOW-UP STUDIES; GASTRECTOMY; HUMAN; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PERITONEAL DISEASES; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035990850     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf212     Document Type: Article

References (19)

1. Gastric carcinoma
2. CT appearance of afferent loop obstruction
3. Roux-en- Y. diversion as an alternate method of reconstruction of the alimentary tract after primary resection of the stomach
4. Surgical treatment of the post-gastrectomy dumping syndrome
5. Percutaneous transhepatic duodenal drainage as an alternative approach in afferent loop obstruction with secondary obstructive jaundice in recurrent gastric cancer
6. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancer: An effective and low-toxic regimen for patients with poor general condition
7. Gastric cancer associated with acute disseminated intravascular coagulation: Successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin
8. Percutaneous bowel drainage for jaundice due to afferent loop obstruction following pancreatoduodenectomy: Report of a case
9. Refractory afferent loop problem: Percutaneous transhepatic management of two cases
10. Palliation of malignant gastric outlet obstruction caused by gastric cancer with self-expandable metal stents
11. Palliation of postoperative GI anastomotic malignant strictures with flexible covered metallic stents: Preliminary results
12. Transhepatic insertion of a metallic stent for the relief of malignant afferent loop syndrome
13. Phase II study with the combination of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer
14. Resectable gastric carcinoma: An evaluation of preoperative and postoperative chemotherapy
15. Clinical pathway for the management of respectable gastric cancer with peritoneal seeding: Best palliation with a ray hope for cure
16. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with gastric cancers
17. Weekly high-dose fluorouracil and folinic acid as salvage treatment in advanced gastric cancer
18. Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer
19. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon α-2a in patients with refractory malignancies of the gastrointestinal tract